Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 7/20 | 0.49 |
| ▸ | KLK5 | Q9Y337 | 7/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.48 |
| ▸ | CTSK | P43235 | 1/20 | 0.48 |
| ▸ | ACE | P12821 | 2/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | AKT1 | P31749 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15020483 | 0.87 | KMT2A (0.40) | KMT2ACTSSCTSLCTSBCTSK | |
| SCHEMBL15047167 | 0.86 | KMT2A (0.52) | KMT2ACTSSCTSLCTSBCTSK | |
| SCHEMBL15020437 | 0.77 | HDAC8 (0.46) | CTSLCTSBCTSK | |
| SCHEMBL13828154 | 0.77 | KMT2A (0.53) | KLK5KMT2ACTSSCTSLCTSB | |
| SCHEMBL16223434 | 0.77 | CTSL (0.36) | KLK7KLK5CTSSCTSLCTSB | |
| SCHEMBL6162796 | 0.76 | KMT2A (0.62) | KMT2ACTSSCTSLCTSBCTSK | |
| SCHEMBL6624940 | 0.76 | KMT2A (0.62) | KMT2ACTSSCTSLCTSBCTSK | |
| SCHEMBL6624367 | 0.76 | KMT2A (0.62) | KMT2ACTSSCTSLCTSBCTSK | |
| SCHEMBL6161955 | 0.76 | KMT2A (0.62) | KMT2ACTSSCTSLCTSBCTSK | |
| SCHEMBL6162598 | 0.76 | KMT2A (0.62) | KMT2ACTSSCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2579887-B1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | SEATTLE GENETICS INC (US) | 2014-11-12 | — | — | EP | disclosed |
| US-8722629-B2 | Auristatin derivatives and use thereof | SEATTLE GENETICS, INC. (US) | 2014-05-13 | — | — | US | disclosed |
| US-20130157960-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | SEATTLE GENETICS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2011154359-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130157960-A1 | NOVEL AURISTATIN DERIVATIVES AND USE THEREOF | AURKC, AURKA, AURKB | KLK7 1472/4885KLK5 1076/4885KMT2A 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.